GlassScriptPhysician profile
Primo N Lara
NPI 1972585743
$9,207.67
in general payments reported to CMS, 2019-2025
14 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,103 · 2022: $139 · 2023: $176 · 2024: $3,653 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,533 · Food and Beverage: $398 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,532.50 |
| Food and Beverage | $398.43 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $3,592.50 | 2024 | Epkinly |
| Merck Sharp & Dohme LLC | $2,883.10 | 2019 | |
| Janssen Scientific Affairs, LLC | $2,192.42 | 2019 | |
| Pfizer INC. | $162.89 | 2024-2025 | |
| Seagen INC. | $138.68 | 2022 | |
| Coherus Oncology, INC. | $115.54 | 2023 | |
| Astellas Pharma US INC | $60.00 | 2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Incyte Corporation | $27.48 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Primo Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.